Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Reversal of Rocuronium-induced Neuromuscular Block Under Mild Hypothermia
NCT01965067Phase 4Completed
- Sponsor
- MSD
- Start
- Oct 2013
- Primary completion
- Feb 2014
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by MSD. Primary endpoint: Reversal Time of Rocuronium. Started Oct 2013; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT01965067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965067.